Investor Relations

About Company

ImmunityBio, Inc. and NantKwest, Inc. merged on March 9, 2021 to create a leading late-stage, cell therapy and immunotherapy company focused on oncology and infectious diseases. The combined company is called ImmunityBio, Inc. (NASDAQ: IBRX).

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date

Oct 13, 2021

National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy

Oct 04, 2021

ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial

Sep 13, 2021

ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives

Sep 07, 2021

Events

Contact Information

IR Contact

ImmunityBio Investor Relations

Phone: 1-844-696-5235, Option 5
Email

Transfer Agent & Stockholder Services

American Stock Transfer & Trust Company, LLC

AST Shareholder Services Call Center
Toll Free: 800.937.5449
Local & International: 718-921-8124
Hours: 8 a.m. – 8 p.m. ET Monday-Friday

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
Email
Website